- Clinical Trials
Genprex is bridging critical gaps in modern medicine by providing new treatments to large patient populations with cancer and diabetes who currently have limited treatment options available to them or are burdened by currently available treatments.
Our oncology program uses a modern combinational treatment approach to fight cancer, utilizing our lead drug candidate, GPX-001 and our unique, proprietary, non-viral Oncoprex™ nanoparticle delivery platform combined with approved targeted therapies and immunotherapies. This enables the us to offer hope to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them.
Our auto-immune disease program is initially targeting diabetes. Our diabetes gene therapy drug candidate, GPX-002, uses an endoscope and an adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes to the pancreas. The genes express proteins that transform alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system. We believe that GPX-002 could provide Type 1 and Type 2 diabetes patients with a new treatment option, possibly even a cure.